# Phase4 Partners

> Phase4 Partners is a VC fund in London backing Art, Apps and Medical. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: London, United Kingdom
- Total investments: 3
- Last investment: Aug 2020
- Lead investor: 33%
- Last updated: Aug 2026
- Website: http://www.phase4-partners.com

Phase4 Partners is a VC fund in London focused on Art and Apps. Long known as one of the leading life science venture capital firms based in Europe, Phase4 Partners, formerly known as Phase4 Ventures, has more recently expanded its mission to include a range of innovative investment vehicles to meet the needs of major pharmaceutical companies as well as sophisticated private and institutional investors fromaround the world.Founded in 1999 with its home office in London, Phase4 has invested over $400 million in 24 companies in both Europe and the US, including such notable successes as Pharmion, Arakis, Proteolix, Albireo, and OncoMed (NASDAQ: OMED). Phase4 is particularly proud of its key role in funding the development of breakthrough products such as Kyprolis (acquired by Onyx when it purchased Proteolix); Ultibro Breezhaler (a Novartis product originally developed by Arakis); and Vidaza and Thalomid (both acquired by Celgene when it purchased Pharmion); as well as important advances now in clinical trials including OncoMed’s line of innovative products directed at blocking cancer stem cells and Albireo’s elobixibat, now in Phase III studies being conducted by Albireo’s partner Ferring. All of these products offer significant improvements in the treatment of serious diseases while having the potential to generate large profits for the companies involved as well as our investors.Phase4 is a member of the British Private Equity and Venture Capital Association (BVCA), and the European Private Equity and Venture Capital Association (EVCA).

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Art | 1 | 33% |
| Apps | 1 | 33% |
| Medical | 1 | 33% |
| Software | 1 | 33% |
| Health Care | 1 | 33% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 33% |
| Series B | 1 | 33% |
| Debt Financing | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Austria | 1 | 33% |
| Czech Republic | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Avocode | Avocode is software that enables its users to export and share anything from Photoshop and Sketch designs, including colors, image assets, fonts, text, CSS, sizes, and dimensions. It acts as a bridge between designers and developers. | $500K | Debt Financing | Aug 07, 2020 |  |
| Avocode | Avocode is software that enables its users to export and share anything from Photoshop and Sketch designs, including colors, image assets, fonts, text, CSS, sizes, and dimensions. It acts as a bridge between designers and developers. | $1M | Seed | May 17, 2016 |  |
| Nabriva Therapeutics | Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA® (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic forcommunity-acquired bacterial pneumonia (CABP). Nabriva Therapeutics is also developing CONTEPO™ (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis. Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO® (tedizolid phosphate) in the United States and certain of its territories. | $120M | Series B | Apr 07, 2015 |  |

3 of 3 investments shown.

## Co-investors
- [500 Global](https://shizune.co/investors/profile/500-startups) — VC Fund, 1 deal together
- [Boxer Capital](https://shizune.co/investors/profile/boxer-capital) — VC Fund, 1 deal together
- [EcoR1 Capital](https://shizune.co/investors/profile/ecor1-capital) — VC Fund, 1 deal together
- [GLS Ventures](https://shizune.co/investors/profile/gls-ventures) — VC Fund, 1 deal together
- [HBM Healthcare Investments](https://shizune.co/investors/profile/hbm-healthcare-investments-ag) — VC Fund, 1 deal together
- [Hustle Fund](https://shizune.co/investors/profile/hustle-fund) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Galaxy Interactive](https://shizune.co/investors/profile/galaxy-interactive) — VC Fund
- [Animoca Brands](https://shizune.co/investors/profile/animoca-brands-corporation) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [Reflex Capital](https://shizune.co/investors/profile/reflex-capital) — VC Fund
- [MITON](https://shizune.co/investors/profile/miton-cz-s-r-o) — VC Fund
- [N1](https://shizune.co/investors/profile/nation-1) — VC Fund

## Featured in investor lists
- [Art Investors in Czech Republic](https://shizune.co/investors/art-investors-czech-republic)

## FAQ

### What does Phase4 Partners invest in?

Phase4 Partners invests primarily in Art, Apps and Medical startups, most often at Seed and Series B stage. Most of the 3 investments tracked by Shizune back companies in Austria. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Phase4 Partners last invest?

The most recent investment recorded for Phase4 Partners closed in Aug 2020. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co